Trial
NCT01122927
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Adolescent Schizophrenia
Intervention
Aripiprazole
Why stopped
The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-08